MO-BATS-GLOBAL-MARKETS
BATS Global Markets (BATS) today reported October highlights including new monthly market share records of 21.4% in U.S. equities and 6.5% in U.S. options.
The previous record for U.S. equities was 20.7% in April 2014 and the previous options record was 5.8% in September 2014. October marked the third consecutive month of record market share for BATS Options.
In Europe, BATS reported 22.3% market share, its strongest month in 2014. Notably, total average daily notional value traded was 45.4% higher than in October 2013. Separately, more than €368.0bn was reported to BXTR, the exchange’s trade reporting facility.
Other October highlights include:
- BATS Options also set a one-day market share record of 7.8% on October 27th . In October, BATS Options reported five days where market share topped 7.0%, a new record for the growing business.
- In October, BATS Chi-X Europe average daily notional value traded totaled €11.0 billion. In the U.S., the BATS Exchanges reported average daily matched volume of 1.67 billion shares, a new record for the company.
- Continental European market share grew in key markets: share of the Frankfurt market increased 2.2 percentage points on October 2013; share of the Milan market was up 1.7 percentage points, and share of the Madrid market was up 3.1 percentage points.
- BATS Chi-X Europe announced the planned launch of trading in Turkish stocks. With the addition of Turkey, BATS will offer trading across 16 markets in Europe.
- BATS Chi-X Europe was recognized at Financial News’ 2014 Awards for Excellence in Trading and Technology, winning four awards. These included Best Equities Trading Platform, Most Innovative Data Product (for BXTR), Post-Trade Initiative of the Year (for ETF interoperability) and CTO of the Year (for Dave Howson).
- BATS welcomed two new U.S. listings to the BZX Exchange in October. The iShares MSCI Emerging Markets Horizon ETF (BATS: EMHZ) commenced trading on October 16th and the ValueShares U.S. Quantitative Value ETF (BATS: QVAL) began trading on October 22nd .
- In the U.S., BATS remains on schedule for the substantive completion of the Direct Edge integration in January 2015. BATS conducted its first weekend test opportunity for members to test the new EDGA and EDGX trading platforms in the Equinix NY5 data center on Saturday, October 11th . Information on the integration process, including a schedule of upcoming test dates, is available at bats.com/edgeintegration .
- BATS Chi-X Europe successfully completed a disaster recovery test on Saturday, October 11th , which simulated various disaster recovery failover scenarios for the Exchange.
October 2014 Volume and Market Share Summary
| U.S. Equities (BATS Exchanges – BZX, BYX, EDGA, EDGX) | October 2014 | |||
| Overall Industry – Average Daily Consolidated Volume | 7.82 billion shares | |||
| BATS Exchanges – Matched Market Share | 21.4% | |||
| BATS Exchanges – Average Daily Matched Volume | 1.67 billion shares | |||
| U.S. Equity Options (BATS Options) | ||||
| BATS Options – Matched Market Share | 6.5% | |||
| BATS Options – Average Daily Matched Volume | 1,364,829 contracts | |||
| European Equities (BATS Chi-X Europe) | ||||
| Pan-European Consolidated Volume1 – Average Daily Notional Value | €49.4 billion | |||
| BATS Chi-X Europe – Overall European Market Share | 22.3% | |||
| BATS Chi-X Europe – Total Notional Value Traded | €252.7 billion | |||
| BATS Chi-X Europe – Average Daily Notional Value | €11.0 billion | |||
| European Trade Reporting (BXTR) | ||||
| BXTR – Total Notional Value Reported | €368.0 billion | |||
| BXTR – Average Daily Notional Value Reported | €16.0 billion |
1 Based on BATS Chi-X Europe market coverage, available at www.batstrading.co.uk
Additional details regarding BATS’ volume and market share data by market – U.S. equities, U.S. equity options, and European equities – is outlined below.
U.S. Equities – BATS Exchanges Volume and Market Share Statistics
Market Quality Statistics
- During October, the BZX Exchange ranked 1st or 2nd in quality of trading in 311 of the stocks in the S&P 500® Index, as measured by effective spread, according to the BATS market quality statistics .
- Combined, the BZX Exchange and EDGX Exchange had the lowest effective spread in 12 of the top 25 exchange-traded products.
| BATS Exchanges (BZX, BYX, EDGA, EDGX) – Market Volume Summary, Volume, and Statistics | |||||||
| October 2014 | October 2013 2 | ||||||
| BATS Exchanges percentage of overall U.S. equities market share | 21.4% | 10.2% | |||||
| Average daily volume (ADV) traded on BATS Exchanges | 1.67 billion shares | 638.8 million shares | |||||
| Total industry volume | 7.82 billion shares | 6.29 million shares | |||||
| Total notional value traded on BATS Exchanges | $1.58 trillion | $570.0 billion | |||||
| Average daily notional value traded on BATS Exchanges | $68.9 billion | $24.8 billion | |||||
| BATS overall market share – Tape A securities | 19.2% | 9.0% | |||||
| BATS overall market share – Tape B securities | 25.9% | 14.5% | |||||
| BATS overall market share – Tape C securities | 22.2% | 9.8% | |||||
| BATS overall market share in ETF trading3 | 26.1% | 15.1% | |||||
| BATS 1000 Index monthly performance and close |
+2.7%
22,546.22 |
+4.3%
19,851.93 |
|||||
2
BATS BZX and BYX Exchange data only
3
Based
on ArcaVision.com data
To track U.S. equities market share for all major trading exchanges and off-exchange trading, please view the BATS U.S. Equities Market Volume Summary .
U.S. Equity Options – BATS Options Volume and Market Share Statistics
- The five most actively-traded options classes on BATS Options during October were the Standard & Poor’s Depositary Receipt ETF Trust (SPY), Apple Inc. (APPL), iShares Russell 2000 Index ETF (IWM), PowerShares QQQ Trust, Series 1 ETF (QQQ), and iPath S&P 500 VIX Short-Term Futures ETN(VXX).
| BATS Options Market Share and Volume | |||||||||||||
| October 2014 | October 2013 | ||||||||||||
| Contracts | Market share | Contracts | Market Share | ||||||||||
| Average daily matched volume | 1,364,829 | 6.5% | 620,750 | 3.6% | |||||||||
To track U.S. options market share for all major trading exchanges, please view the BATS U.S. Options Market Volume Summary .
European Equities – BATS Chi-X Europe Volume and Market Share Statistics
To track European market share for all major trading exchanges and other venues, please view the BATS Pan-European Market Volume Summary .
| BATS Chi-X Europe Market Share by Market 2 | |||||||
| October 2014 | October 2013 | ||||||
| (In millions, except percentages) | |||||||
| BATS Chi-X Europe overall market share | 22.3% | 22.9% | |||||
| BATS Chi-X Europe Average daily notional value | €10,988.9 | €7,781.0 | |||||
| Displayed average daily notional value | €9,921.8 | €7,049.9 | |||||
| Non-displayed3 average daily notional value | €1,067.1 | €731.1 | |||||
| London market overall | 23.5% | 27.3% | |||||
| FTSE 100 securities | 25.0% | 30.6% | |||||
| FTSE 250 securities | 22.3% | 21.7% | |||||
| Nordic market overall | 23.7% | 27.2% | |||||
| Helsinki OMXH25 securities | 23.9% | 29.6% | |||||
| Stockholm OMXS30 securities | 26.5% | 30.1% | |||||
| Copenhagen OMXC20 securities | 22.1% | 24.0 % | |||||
| Oslo OBX securities | 21.3% | 23.0% | |||||
| Frankfurt market overall | 27.1% | 24.9% | |||||
| DAX 30 securities | 28.9% | 26.6% | |||||
| MDAX securities | 28.9% | 23.7% | |||||
| SDAX securities | 11.0% | 8.5% | |||||
| Zurich market overall | 20.0% | 24.1% | |||||
| SMI securities | 21.7% | 26.2% | |||||
| SMIM securities | 19.6% | 17.8% | |||||
| Paris market overall | 23.8% | 23.3% | |||||
| CAC 40 securities | 24.0% | 24.3% | |||||
| CAC Next20 securities | 26.8% | 23.5% | |||||
| Brussels market overall | 24.2% | 22.7% | |||||
| BEL 20 securities | 23.6% | 24.3% | |||||
| Amsterdam market overall | 21.7% | 22.2% | |||||
| AEX securities | 22.2% | 22.7% | |||||
| AMX securities | 20.9% | 18.1% | |||||
| Vienna market overall | 20.5% | 15.8% | |||||
| ATX securities | 21.2% | 16.6% | |||||
| Milan market overall | 13.6% | 11.8% | |||||
| FTSE MIB securities | 14.1% | 12.7% | |||||
| Madrid market overall | 16.1% | 13.0% | |||||
| IBEX 35 securities | 16.6% | 13.9% | |||||
| Lisbon market overall | 12.1% | 10.5% | |||||
| PSI-20 securities | 12.2% | 10.6% | |||||
| Dublin market overall | 10.9% | 6.7% | |||||
| ISEQ 20 securities | 10.9% | 6.7% | |||||
| Key Indices | |||||||
| EUROSTOXX 50 securities | 22.5% | 22.1% | |||||
| FTSE RIOB | 6.5% | 9.6% | |||||
2
Represent consolidated figures for BXE and CXE lit
and dark books, unless otherwise noted.
3
BXE and
CXE non-displayed order books.
About BATS Global Markets, Inc.
BATS Global Markets, Inc. is a leading global operator of securities markets, committed to Making Markets Better for traders, investors and issuers. In the U.S., BATS operates four stock exchanges – BZX, BYX, EDGX and EDGA – and regularly ranks as the top market for ETF and retail-driven liquidity. The company is an important listing venue for ETFs and other structured products and also operates BATS Options, a U.S. equity options market. In Europe, BATS operates the largest pan-European equities exchange, offering trading and listing services across 15 major European markets. With its world-class proprietary technology and relentless customer focus, BATS strives to bring efficiency, transparency and fairness to market participants. The company is headquartered in Kansas City with offices in Chicago, the New York area and London. Further information on BATS can be found at www.bats.com and by following us on Twitter @BATSGlobal .
Contact:
BATS Global Markets, Inc.
Media:
Jim Gorman
(NYC), +1-201-942-8234
Stacie Fleming (KC) +1-913-815-7193
Hannah
Randall (London) +44-207-012-8950
comms@bats.com
or
Analysts:
Randy
Williams (NYC), +1-212-378-8522
rwilliams@bats.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 09:15:00 CEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release
Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release
New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum